Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease

World Journal of Gastroenterology

Volumn 20, Issue 45, 2014, Pages 16841-16857

  Federico, Alessandro ^a   Zulli, Claudio ^a   De Sio, Ilario ^a   Prete, Anna Del ^a   Dallio, Marcello ^a   Masarone, Mario ^b   Loguercio, Carmela ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

Emerging drugs; Fatty liver; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Steatosis

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID RECEPTOR AGONIST; CYTOPROTECTIVE AGENT; ENZYME INHIBITOR; FARNESOID X RECEPTOR AGONIST; GLITAZONE DERIVATIVE; HERBACEOUS AGENT; HORMONE RECEPTOR STIMULATING AGENT; METFORMIN; OXIDIZING AGENT; PENTOXIFYLLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PROBIOTIC AGENT; PROBUCOL; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; ANTILIPEMIC AGENT; ANTIOBESITY AGENT; CHOLAGOGUE;

APOPTOSIS; ARTICLE; DIET RESTRICTION; DRUG EFFICACY; DRUG RESEARCH; DRUG RESPONSE; ENZYME INHIBITION; EXERCISE; HUMAN; HYPERGLYCEMIA; INFLAMMATION; IRON DEPLETION; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONALCOHOLIC FATTY LIVER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); WEIGHT REDUCTION; ANIMAL; BEHAVIOR THERAPY; BLOOD; COMORBIDITY; INSULIN RESISTANCE; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY; RISK FACTOR; RISK REDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTI-OBESITY AGENTS; BEHAVIOR THERAPY; CHOLAGOGUES AND CHOLERETICS; COMORBIDITY; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INSULIN RESISTANCE; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84917696613     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i45.16841     Document Type: Article

References (137)

1. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010; 28: 155-161 [PMID: 20460905 DOI: 10.1159/000282080]
2. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419 [PMID: 10348825]
3. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923 [PMID: 12668987]
4. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Zvibel I, Goldiner I, Blendis L, Halpern Z, Oren R. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology 2008; 48: 1791-1798 [PMID: 18972405 DOI: 10.1002/hep.22525]
5. Newton JL, Jones DE, Henderson E, Kane L, Wilton K, Burt AD, Day CP. Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut 2008; 57: 807-813 [PMID: 18270241 DOI: 10.1136/gut.2007.139303]
6. Tsochatzis E, Papatheodoridis GV, Manesis EK, Kafiri G, Tiniakos DG, Archimandritis AJ. Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008; 27: 80-89 [PMID: 17919273]
7. Tsochatzis EA, Manolakopoulos S, Papatheodoridis GV, Archimandritis AJ. Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications. Scand J Gastroenterol 2009; 44: 6-14 [PMID: 18661429 DOI: 10.1080/00365520802273058]
8. Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm 2009; 2009: 831670 [PMID: 19753129 DOI: 10.1155/2009/831670]
9. Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol 2006; 101: 2629-2640 [PMID: 16952281]
10. Svetkey LP, Stevens VJ, Brantley PJ, Appel LJ, Hollis JF, Loria CM, Vollmer WM, Gullion CM, Funk K, Smith P, Samuel-Hodge C, Myers V, Lien LF, Laferriere D, Kennedy B, Jerome GJ, Heinith F, Harsha DW, Evans P, Erlinger TP, Dalcin AT, Coughlin J, Charleston J, Champagne CM, Bauck A, Ard JD, Aicher K. Comparison of strategies for sustaining weight loss: the weight loss maintenance randomized controlled trial. JAMA 2008; 299: 1139-1148 [PMID: 18334689 DOI: 10.1001/jama.299.10.1139]
11. Tilg H, Moschen A. Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol 2010; 56: 159-167 [PMID: 20485253]
12. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592-1609 [PMID: 22656328 DOI: 10.1053/j.gastro.2012.04.001]
13. Rinella ME, Loomba R, Caldwell SH, Kowdley K, Charlton M, Tetri B, Harrison SA. Controversies in the Diagnosis and Management of NAFLD and NASH. Gastroenterol Hepatol (N Y) 2014; 10: 219-227 [PMID: 24976805]
14. Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol 2012; 56: 255-266 [PMID: 21723839 DOI: 10.1016/j.jhep.2011.06.010]
15. Larson-Meyer DE, Newcomer BR, Heilbronn LK, Volaufova J, Smith SR, Alfonso AJ, Lefevre M, Rood JC, Williamson DA, Ravussin E. Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function. Obesity (Silver Spring) 2008; 16: 1355-1362 [PMID: 18421281 DOI: 10.1038/oby.2008.201]
16. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012; 55: 885-904 [PMID: 22278337 DOI: 10.1007/s00125-011-2446-4]
17. Gao X, Fan JG; Study Group of Liver and Metabolism, Chinese Society of Endocrinology. Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology. J Diabetes 2013; 5: 406-415 [PMID: 23560695 DOI: 10.1111/1753-0407.12056]
18. Musso G, Gambino R, Cassader M, Pagano G. A metaanalysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52: 79-104 [PMID: 20578268 DOI: 10.1002/hep.23623]
19. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009; 49: 306-317 [PMID: 19065650 DOI: 10.1002/hep.22603]
20. Kashi MR, Torres DM, Harrison SA. Current and emerging therapies in nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28: 396-406 [PMID: 18956296 DOI: 10.1055/s-0028-1091984]
21. Capristo E, Miele L, Forgione A, Vero V, Farnetti S, Mingrone G, Greco AV, Gasbarrini G, Grieco A. Nutritional aspects in patients with non-alcoholic steatohepatitis (NASH). Eur Rev Med Pharmacol Sci 2005; 9: 265-268 [PMID: 16231587]
22. Cortez-Pinto H, Jesus L, Barros H, Lopes C, Moura MC, Camilo ME. How different is the dietary pattern in nonalcoholic steatohepatitis patients? Clin Nutr 2006; 25: 816-823 [PMID: 16677739]
23. Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, Fag E, Silli B, Pagano G. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003; 37: 909-916 [PMID: 12668986]
24. Musso G, Gambino R, De Michieli F, Biroli G, Premoli A, Pagano G, Bo S, Durazzo M, Cassader M. Nitrosative stress predicts the presence and severity of nonalcoholic fatty liver at different stages of the development of insulin resistance and metabolic syndrome: possible role of vitamin A intake. Am J Clin Nutr 2007; 86: 661-671 [PMID: 17823431]
25. Yilmaz Y. Review article: fructose in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012; 35: 1135-1144 [PMID: 22469071 DOI: 10.1111/j.1365-2036.2012.05080.x]
26. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991; 12: 224-229 [PMID: 2051001]
27. Asrih M, Jornayvaz FR. Diets and nonalcoholic fatty liver disease: the good and the bad. Clin Nutr 2014; 33: 186-190 [PMID: 24262589 DOI: 10.1016/j.clnu.2013.11.003]
28. Toshimitsu K, Matsuura B, Ohkubo I, Niiya T, Furukawa S, Hiasa Y, Kawamura M, Ebihara K, Onji M. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition 2007; 23: 46-52 [PMID: 17140767]
29. Zelber-Sagi S, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol 2011; 17: 3377-3389 [PMID: 21876630 DOI: 10.3748/wjg.v17.i29.3377]
30. Yasutake K, Kohjima M, Kotoh K, Nakashima M, Nakamuta M, Enjoji M. Dietary habits and behaviors associated with nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20: 1756-1767 [PMID: 24587653 DOI: 10.3748/wjg.v20.i7.1756]
31. de Luis DA, Aller R, Izaola O, Gonzalez Sagrado M, Conde R. Effect of two different hypocaloric diets in transaminases and insulin resistance in nonalcoholic fatty liver disease and obese patients. Nutr Hosp 2010; 25: 730-735 [PMID: 21336428]
32. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Blendis L, Halpern Z, Oren R. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 2007; 47: 711-717 [PMID: 17850914 DOI: 10.1016/j.jhep.2007.06.020]
33. Yasutake K, Nakamuta M, Shima Y, Ohyama A, Masuda K, Haruta N, Fujino T, Aoyagi Y, Fukuizumi K, Yoshimoto T, Takemoto R, Miyahara T, Harada N, Hayata F, Nakashima M, Enjoji M. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. Scand J Gastroenterol 2009; 44: 471-477 [PMID: 19058085 DOI: 10.1080/00365520802588133]
34. Centis E, Marzocchi R, Suppini A, Dalle Grave R, Villanova N, Hickman IJ, Marchesini G. The role of lifestyle change in the prevention and treatment of NAFLD. Curr Pharm Des 2013; 19: 5270-5279 [PMID: 23394095]
35. Finelli C, Tarantino G. Have guidelines addressing physical activity been established in nonalcoholic fatty liver disease? World J Gastroenterol 2012; 18: 6790-6800 [PMID: 23239917 DOI: 10.3748/wjg.v18.i46.6790]
36. Ross AB, Godin JP, Minehira K, Kirwan JP. Increasing whole grain intake as part of prevention and treatment of nonalcoholic Fatty liver disease. Int J Endocrinol 2013; 2013: 585876 [PMID: 23762052 DOI: 10.1155/2013/585876]
37. Utzschneider KM, Bayer-Carter JL, Arbuckle MD, Tidwell JM, Richards TL, Craft S. Beneficial effect of a weight-stable, low-fat/low-saturated fat/low-glycaemic index diet to reduce liver fat in older subjects. Br J Nutr 2013; 109: 1096-1104 [PMID: 22849970 DOI: 10.1017/S0007114512002966]
38. Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M, Leshno M, Blendis L, Halpern Z, Oren R. A doubleblind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4: 639-644 [PMID: 16630771]
39. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 2009; 49: 80-86 [PMID: 19053049 DOI: 10.1002/hep.22575]
40. Mallat A, Lotersztajn S. Endocannabinoids and their role in fatty liver disease. Dig Dis 2010; 28: 261-266 [PMID: 20460921 DOI: 10.1159/000282100]
41. Alswat KA. The role of endocannabinoids system in fatty liver disease and therapeutic potentials. Saudi J Gastroenterol 2013; 19: 144-151 [PMID: 23828743 DOI: 10.4103/1319-3767.1 14505]
42. Deveaux V, Cadoudal T, Ichigotani Y, Teixeira-Clerc F, Louvet A, Manin S, Nhieu JT, Belot MP, Zimmer A, Even P, Cani PD, Knauf C, Burcelin R, Bertola A, Le Marchand-Brustel Y, Gual P, Mallat A, Lotersztajn S. Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One 2009; 4: e5844 [PMID: 19513120 DOI: 10.1371/journal.pone.0005844]
43. Julien B, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, Karsak M, Zimmer A, Mallat A, Lotersztajn S. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005; 128: 742-755 [PMID: 15765409]
44. Wierzbicki AS, Pendleton S, McMahon Z, Dar A, Oben J, Crook MA, Botha AJ. Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study. Int J Clin Pract 2011; 65: 713-715 [PMID: 21564446 DOI: 10.1111/j.1742-1241.2011.02683.x]
45. Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev 2010; 11: 430-445 [PMID: 19845871 DOI: 10.1111/j.1467- 789X.2009.00657.x]
46. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Ünalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011; 305: 1659-1668 [PMID: 21521847]
47. Tsochatzis EA, Papatheodoridis GV. Is there any progress in the treatment of non-alcoholic fatty liver disease? World J Gastrointest Pharmacol Ther 2011; 2: 1-5 [PMID: 21577310 DOI: 10.4292/wjgpt.v2.i1.1]
48. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023 [PMID: 22488764 DOI: 10.1002/hep.25762]
49. Van Wagner LB, Rinella ME. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2011; 4: 249-263 [PMID: 21765869 DOI: 10.1177/1756283X11403809]
50. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685 [PMID: 20427778 DOI: 10.1056/NEJMoa0907929]
51. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-2307 [PMID: 17135584]
52. Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, Borg B, Loomba R, Liang TJ, Premkumar A, Hoofnagle JH. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007; 46: 424-429 [PMID: 17559148]
53. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157 [PMID: 17498508]
54. Byetta (exenatide) injection: US prescribing information (revised December 2011). San Diego, CA: Amylin Pharmaceuticals, Inc., 2011
55. Victoza (liraglutide[rDNA origin] injection) solution for subcutaneous use: US prescribing information (revised April 2012). Princeton, NJ: Novo Nordisk Inc, 2012
56. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9: 194-205 [PMID: 17300595]
57. Svegliati-Baroni G, Saccomanno S, Rychlicki C, Agostinelli L, De Minicis S, Candelaresi C, Faraci G, Pacetti D, Vivarelli M, Nicolini D, Garelli P, Casini A, Manco M, Mingrone G, Risaliti A, Frega GN, Benedetti A, Gastaldelli A. Glucagonlike peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int 2011; 31: 1285-1297 [PMID: 21745271 DOI: 10.1111/j.1478-3231.2011.02462.x]
58. Fan H, Pan Q, Xu Y, Yang X. Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. Arq Bras Endocrinol Metabol 2013; 57: 702-708 [PMID: 24402015]
59. Shirakawa J, Fujii H, Ohnuma K, Sato K, Ito Y, Kaji M, Sakamoto E, Koganei M, Sasaki H, Nagashima Y, Amo K, Aoki K, Morimoto C, Takeda E, Terauchi Y. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 2011; 60: 1246-1257 [PMID: 21330637 DOI: 10.2337/db10-1338]
60. Iwasaki T, Yoneda M, Inamori M, Shirakawa J, Higurashi T, Maeda S, Terauchi Y, Nakajima A. Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus. Hepatogastroenterology 2011; 58: 2103-2105 [PMID: 22024083 DOI: 10.5754/hge11263]
61. Olaywi M, Bhatia T, Anand S, Singhal S. Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review. Hepatobiliary Pancreat Dis Int 2013; 12: 584-588 [PMID: 24322742]
62. Katsuno K, Fujimori Y, Ishikawa-Takemura Y, Isaji M. Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice. Eur J Pharmacol 2009; 618: 98-104 [PMID: 19615995 DOI: 10.1016/j.ejphar.2009.07.001]
63. Nseir W, Mograbi J, Ghali M. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies. Dig Dis Sci 2012; 57: 1773-1781 [PMID: 22419057 DOI: 10.1007/s10620-012-2118-3]
64. Merat S, Aduli M, Kazemi R, Sotoudeh M, Sedighi N, Sohrabi M, Malekzadeh R. Liver histology changes in nonalcoholic steatohepatitis after one year of treatment with probucol. Dig Dis Sci 2008; 53: 2246-2250 [PMID: 18049900]
65. Merat S, Malekzadeh R, Sohrabi MR, Sotoudeh M, Rakhshani N, Sohrabpour AA, Naserimoghadam S. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatol 2003; 38: 414-418 [PMID: 12663231]
66. Pathil A, Mueller J, Warth A, Chamulitrat W, Stremmel W. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. Hepatology 2012; 55: 1369-1378 [PMID: 22183915 DOI: 10.1002/hep.25531]
67. Xiang Z, Chen YP, Ma KF, Ye YF, Zheng L, Yang YD, Li YM, Jin X. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol 2013; 13: 140 [PMID: 24053454 DOI: 10.1186/1471-230X-13-140]
68. Ratziu V. Treatment of NASH with ursodeoxycholic acid: pro. Clin Res Hepatol Gastroenterol 2012; 36 Suppl 1: S41-S45 [PMID: 23141893 DOI: 10.1016/S2210-7401(12)70020-7]
69. Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rössle M, Cordes HJ, Zeuzem S, Hein J, Berg T. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010; 52: 472-479 [PMID: 20683947 DOI: 10.1002/hep.23727]
70. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L, Colin P. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004; 39: 770-778 [PMID: 14999696]
71. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003; 98: 2485-2490 [PMID: 14638353]
72. Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, Zala JF, Helbling B, Steuerwald M, Zimmermann A. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006; 4: 1537-1543 [PMID: 17162245]
73. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, Shiffman ML, Clore J, Mills AS. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004; 2: 1107-1115 [PMID: 15625656]
74. Sumida Y, Naito Y, Tanaka S, Sakai K, Inada Y, Taketani H, Kanemasa K, Yasui K, Itoh Y, Okanoue T, Yoshikawa T. Long-term (& gt; =2 yr) efficacy of vitamin E for non-alcoholic steatohepatitis. Hepatogastroenterology 2013; 60: 1445-1450 [PMID: 23933938 DOI: 10.5754/hge11421]
75. Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 37-46 [PMID: 15537682]
76. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007; 297: 842-857 [PMID: 17327526]
77. Del Prete A, Scalera A, Iadevaia MD, Miranda A, Zulli C, Gaeta L, Tuccillo C, Federico A, Loguercio C. Herbal products: benefits, limits, and applications in chronic liver disease. Evid Based Complement Alternat Med 2012; 2012: 837939 [PMID: 22991573]
78. Matveev AV, Koniaeva EI, Kurchenko VP, Shchekatikhina AS. [Hepatoprotective properties of silymarin]. Eksp Klin Gastroenterol 2011; (2): 130-135 [PMID: 21560654]
79. Loguercio C, Federico A, Trappoliere M, Tuccillo C, de Sio I, Di Leva A, Niosi M, DAuria MV, Capasso R, Del Vecchio Blanco C. The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci 2007; 52: 2387-2395 [PMID: 17410454]
80. Boots AW, Wilms LC, Swennen EL, Kleinjans JC, Bast A, Haenen GR. In vitro and ex vivo anti-inflammatory activity of quercetin in healthy volunteers. Nutrition 2008; 24: 703-710 [PMID: 18549926 DOI: 10.1016/j.nut.2008.03.023]
81. Mukherjee S. Betaine and nonalcoholic steatohepatitis: back to the future? World J Gastroenterol 2011; 17: 3663-3664 [PMID: 21990946 DOI: 10.3748/wjg.v17.i32.3663]
82. Wang Z, Yao T, Pini M, Zhou Z, Fantuzzi G, Song Z. Betaine improved adipose tissue function in mice fed a high-fat diet: a mechanism for hepatoprotective effect of betaine in nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol 2010; 298: G634-G642 [PMID: 20203061]
83. Song Z, Deaciuc I, Zhou Z, Song M, Chen T, Hill D, McClain CJ. Involvement of AMP-activated protein kinase in beneficial effects of betaine on high-sucrose diet-induced hepatic steatosis. Am J Physiol Gastrointest Liver Physiol 2007; 293: G894-G902 [PMID: 17702954]
84. Imajo K, Yoneda M, Ogawa Y, Wada K, Nakajima A. Microbiota and nonalcoholic steatohepatitis. Semin Immunopathol 2014; 36: 115-132 [PMID: 24337650 DOI: 10.1007/s00281-013-0404-6]
85. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, Mascian R, Forgione A, Gabrieli ML, Perotti G, Vecchio FM, Rapaccini G, Gasbarrini G, Day CP, Grieco A. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1877-1887 [PMID: 19291785 DOI: 10.1002/hep.22848]
86. Loguercio C, Federico A, Tuccillo C, Terracciano F, DAuria MV, De Simone C, Del Vecchio Blanco C. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005; 39: 540-543 [PMID: 15942443]
87. Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, De La Fuente B, Gonzalez J. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 2011; 15: 1090-1095 [PMID: 22013734]
88. Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 2013; 19: 6911-6918 [PMID: 24187469 DOI: 10.3748/wjg.v19.i40.6911]
89. Kelishadi R, Farajian S, Mirlohi M. Probiotics as a novel treatment for non-alcoholic Fatty liver disease; a systematic review on the current evidences. Hepat Mon 2013; 13: e7233 [PMID: 23885277 DOI: 10.5812/hepatmon.7233]
90. Vajro P, Mandato C, Licenziati MR, Franzese A, Vitale DF, Lenta S, Caropreso M, Vallone G, Meli R. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 2011; 52: 740-743 [PMID: 21505361 DOI: 10.1097/MPG.0b013e31821f9b85]
91. Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, Mastrojeni S, Malaguarnera G, Mistretta A, Li Volti G, Galvano F. Bifidobacterium longum with fructooligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 2012; 57: 545-553 [PMID: 21901256 DOI: 10.1007/s10620-011-1887-4]
92. Wong VW, Won GL, Chim AM, Chu WC, Yeung DK, Li KC, Chan HL. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol 2013; 12: 256-262 [PMID: 23396737]
93. Barbuio R, Milanski M, Bertolo MB, Saad MJ, Velloso LA. Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J Endocrinol 2007; 194: 539-550 [PMID: 17761893]
94. Koca SS, Bahcecioglu IH, Poyrazoglu OK, Ozercan IH, Sahin K, Ustundag B. The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and cholinedeficient diet. Inflammation 2008; 31: 91-98 [PMID: 18066656]
95. Paschos P, Tziomalos K. Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment. World J Hepatol 2012; 4: 327-331 [PMID: 23355909 DOI: 10.4254/wjh.v4.i12.327]
96. Qiang G, Zhang L, Yang X, Xuan Q, Shi L, Zhang H, Chen B, Li X, Zu M, Zhou D, Guo J, Yang H, Du G. Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes. Eur J Pharmacol 2012; 685: 156-164 [PMID: 22546234 DOI: 10.1016/j.ejphar.2012.04.028]
97. Xu W, Song S, Huang Y, Gong Z. Effects of perindopril and valsartan on expression of transforming growth factor-beta- Smads in experimental hepatic fibrosis in rats. J Gastroenterol Hepatol 2006; 21: 1250-1256 [PMID: 16872305]
98. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, McCullough AJ. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011; 54: 1610-1619 [PMID: 21748765]
99. Zein CO, Lopez R, Fu X, Kirwan JP, Yerian LM, McCullough AJ, Hazen SL, Feldstein AE. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology 2012; 56: 1291-1299 [PMID: 22505276 DOI: 10.1002/hep.25778]
100. Valenti L, Dongiovanni P, Fargion S. Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease. World J Gastroenterol 2012; 18: 3782-3786 [PMID: 22876027 DOI: 10.3748/wjg.v18.i29.3782]
101. Beaton MD, Chakrabarti S, Levstik M, Speechley M, Marotta P, Adams P. Phase II clinical trial of phlebotomy for nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2013; 37: 720-729 [PMID: 23441892 DOI: 10.1111/apt.12255]
102. Dixon LJ, Berk M, Thapaliya S, Papouchado BG, Feldstein AE. Caspase-1-mediated regulation of fibrogenesis in dietinduced steatohepatitis. Lab Invest 2012; 92: 713-723 [PMID: 22411067 DOI: 10.1038/labinvest.2012.45]
103. MacKenzie SH, Schipper JL, Clark AC. The potential for caspases in drug discovery. Curr Opin Drug Discov Devel 2010; 13: 568-576 [PMID: 20812148]
104. Anstee QM, Concas D, Kudo H, Levene A, Pollard J, Charlton P, Thomas HC, Thursz MR, Goldin RD. Impact of pan- caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J Hepatol 2010; 53: 542-550 [PMID: 20557969 DOI: 10.1016/j.jhep.2010.03.016]
105. Hatting M, Zhao G, Schumacher F, Sellge G, Al Masaoudi M, Gabler N, Boekschoten M, Müller M, Liedtke C, Cubero FJ, Trautwein C. Hepatocyte caspase-8 is an essential modulator of steatohepatitis in rodents. Hepatology 2013; 57: 2189-2201 [PMID: 23339067 DOI: 10.1002/hep.26271]
106. Ratziu V, Sheikh MY, Sanyal AJ, Lim JK, Conjeevaram H, Chalasani N, Abdelmalek M, Bakken A, Renou C, Palmer M, Levine RA, Bhandari BR, Cornpropst M, Liang W, King B, Mondou E, Rousseau FS, McHutchison J, Chojkier M. A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology 2012; 55: 419-428 [PMID: 22006541 DOI: 10.1002/hep.24747]
107. Robson SC, Schuppan D. Adenosine: tipping the balance towards hepatic steatosis and fibrosis. J Hepatol 2010; 52: 941-943 [PMID: 20395005 DOI: 10.1016/j.jhep.2010.02.009]
108. Imarisio C, Alchera E, Sutti S, Valente G, Boccafoschi F, Albano E, Carini R. Adenosine A(2a) receptor stimulation prevents hepatocyte lipotoxicity and non-alcoholic steatohepatitis (NASH) in rats. Clin Sci (Lond) 2012; 123: 323-332 [PMID: 22439844 DOI: 10.1042/CS20110504]
109. Peng Z, Borea PA, Varani K, Wilder T, Yee H, Chiriboga L, Blackburn MR, Azzena G, Resta G, Cronstein BN. Adenosine signaling contributes to ethanol-induced fatty liver in mice. J Clin Invest 2009; 119: 582-594 [PMID: 19221436 DOI: 10.1172/JCI37409]
110. Cariou B, Zaor Y, Staels B, Bruckert E. Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 2011; 34: 2008-2014 [PMID: 21816979 DOI: 10.2337/dc11-0093]
111. Naturalpha Premier Research Group. Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH). Sep. 2007. Available from: URL: http://clinicaltrials.gov/show/NCT01694849
112. Nagasawa T, Inada Y, Nakano S, Tamura T, Takahashi T, Maruyama K, Yamazaki Y, Kuroda J, Shibata N. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 2006; 536: 182-191 [PMID: 16574099]
113. Larter CZ, Yeh MM, Van Rooyen DM, Brooling J, Ghatora K, Farrell GC. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2012; 27: 341-350 [PMID: 21929649 DOI: 10.1111/j.1440-1746.2011.06939.x]
114. Phase 1 pharmacokinetic study of CP 945598. Clincial trials. Gov identifier: NCT00706537. Last accessed on 2013 Apr 10. Available from: URL: http://clinicaltrials.gov/ct2/show/NCT00706537?term=Cannabinoid and rank=73
115. Study to assess the effect of cannabidiol on liver fat levels in subjects with fatty liver disease. Last accessed on 2014 Apr 04. Available from: URL: http://clinicaltrials.gov/ct2/show/NCT01284634?term=cannabidiol and rank=5 116
116. GWMD1092 GW42003: GW42004 Together plus alone in type II diabetes. Last accessed on 2014 Apr 03. Available from: URL: http://clinicaltrials.gov/ct2/show/NCT01217112
117. Mallat A, Teixeira-Clerc F, Lotersztajn S. Cannabinoid signaling and liver therapeutics. J Hepatol 2013; 59: 891-896 [PMID: 23567085 DOI: 10.1016/j.jhep.2013.03.032]
118. Li Y, Jadhav K, Zhang Y. Bile acid receptors in non-alcoholic fatty liver disease. Biochem Pharmacol 2013; 86: 1517-1524 [PMID: 23988487 DOI: 10.1016/j.bcp.2013.08.015]
119. Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today 2012; 17: 988-997 [PMID: 22652341 DOI: 10.1016/j.drudis.2012.05.012]
120. Hollman DA, Milona A, van Erpecum KJ, van Mil SW. Antiinflammatory and metabolic actions of FXR: insights into molecular mechanisms. Biochim Biophys Acta 2012; 1821: 1443-1452 [PMID: 22820415 DOI: 10.1016/j.bbalip.2012.07.004]
121. Xiong X, Wang X, Lu Y, Wang E, Zhang Z, Yang J, Zhang H, Li X. Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice. J Hepatol 2014; 60: 847-854 [PMID: 24333182 DOI: 10.1016/j.jhep.2013.12.003]
122. Zhang Y, Edwards PA. FXR signaling in metabolic disease. FEBS Lett 2008; 582: 10-18 [PMID: 18023284 DOI: 10.1016/j.jhep.2009.03.025]
123. Abel U, Schlüter T, Schulz A, Hambruch E, Steeneck C, Hornberger M, Hoffmann T, Perović-Ottstadt S, Kinzel O, Burnet M, Deuschle U, Kremoser C. Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists. Bioorg Med Chem Lett 2010; 20: 4911-4917 [PMID: 20638278 DOI: 10.1016/j.bmcl.2010.06.084]
124. McMahan RH, Wang XX, Cheng LL, Krisko T, Smith M, El Kasmi K, Pruzanski M, Adorini L, Golden-Mason L, Levi M, Rosen HR. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J Biol Chem 2013; 288: 11761-11770 [PMID: 23460643 DOI: 10.1074/jbc.M112.446575]
125. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial (FLINT). Last accessed on October 2013. Available from: URL: http://clinicaltrial. gov/ct2/show/NCT01265498
126. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 574-582.e1 [PMID: 23727264 DOI: 10.1053/j.gastro.2013.05.042]
127. Rodgers JT, Puigserver P. Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proc Natl Acad Sci USA 2007; 104: 12861-12866 [PMID: 17646659]
128. Feige JN, Auwerx J. Transcriptional coregulators in the control of energy homeostasis. Trends Cell Biol 2007; 17: 292-301 [PMID: 17475497]
129. Coppola M, Glinni D, Moreno M, Cioffi F, Silvestri E, Goglia F. Thyroid hormone analogues and derivatives: Actions in fatty liver. World J Hepatol 2014; 6: 114-129 [PMID: 24672641]
130. Perra A, Simbula G, Simbula M, Pibiri M, Kowalik MA, Sulas P, Cocco MT, Ledda-Columbano GM, Columbano A. Thyroid hormone (T3) and TRbeta agonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats. FASEB J 2008; 22: 2981-2989 [PMID: 18434432 DOI: 10.1096/fj.08-108464]
131. Antonelli A, Fallahi P, Ferrari SM, Di Domenicantonio A, Moreno M, Lanni A, Goglia F. 3,5-diiodo-L-thyronine increases resting metabolic rate and reduces body weight without undesirable side effects. J Biol Regul Homeost Agents 2011; 25: 655-660 [PMID: 22217997]
132. Lanni A, Moreno M, Lombardi A, de Lange P, Silvestri E, Ragni M, Farina P, Baccari GC, Fallahi P, Antonelli A, Goglia F. 3,5-diiodo-L-thyronine powerfully reduces adiposity in rats by increasing the burning of fats. FASEB J 2005; 19: 1552-1554 [PMID: 16014396]
133. Mollica MP, Lionetti L, Moreno M, Lombardi A, De Lange P, Antonelli A, Lanni A, Cavaliere G, Barletta A, Goglia F. 3,5-diiodo-l-thyronine, by modulating mitochondrial functions, reverses hepatic fat accumulation in rats fed a highfat diet. J Hepatol 2009; 51: 363-370 [PMID: 19464748 DOI: 10.1016/j.jhep.2009.03.023]
134. de Lange P, Cioffi F, Senese R, Moreno M, Lombardi A, Silvestri E, De Matteis R, Lionetti L, Mollica MP, Goglia F, Lanni A. Nonthyrotoxic prevention of diet-induced insulin resistance by 3,5-diiodo-L-thyronine in rats. Diabetes 2011; 60: 2730-2739 [PMID: 21926273 DOI: 10.2337/db11-0207]
135. Zambad SP, Munshi S, Dubey A, Gupta R, Busiello RA, Lanni A, Goglia F, Gupta RC, Chauthaiwale V, Dutt C. TRC150094 attenuates progression of nontraditional cardiovascular risk factors associated with obesity and type 2 diabetes in obese ZSF1 rats. Diabetes Metab Syndr Obes 2011; 4: 5-16 [PMID: 21448317 DOI: 10.2147/DMSOTT.S15323]
136. Kuhajda FP, Ronnett GV. Modulation of carnitine palmitoyltransferase- 1 for the treatment of obesity. Curr Opin Investig Drugs 2007; 8: 312-317 [PMID: 17458181]
137. Schreurs M, Kuipers F, van der Leij FR. Regulatory enzymes of mitochondrial beta-oxidation as targets for treatment of the metabolic syndrome. Obes Rev 2010; 11: 380-388 [PMID: 19694967 DOI: 10.1111/j.1467-789X.2009.00642.x]